Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 18, 2008

Wyeth Takes Over Thiakis for $30M

  • Wyeth Pharmaceuticals acquired Thiakis for approximately $30 million. Additional payments of up to $120 million will be payable upon the achievement of certain development milestones.

    Thiakis' lead product candidate, TKS1225, is being studied for the treatment of obesity and other co-morbidities. TKS1225 and related compounds are synthetic versions of the natural gastrointestinal peptide oxyntomodulin.

    “Thiakis' research and development program fits well with our goal of addressing the medical burden of obesity in a targeted manner using biologic-based therapies," says Mikael Dolsten, M.D., Ph.D., president, Wyeth Research.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »